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pute heterogeneity ( ≥ 15% difference in tissue destruction) 
between (inter-) and within (intra-) lobes for each patient. 
Emphysema tissue destruction was characterized segmen-
tally to define patterns of heterogeneity.  Results: Segmental 
tissue destruction revealed interlobar heterogeneity in the 
left lung (57%) and right lung (52%). Intralobar heterogene-
ity was observed in at least one lobe of all patients. No pa-
tient presented true homogeneity at a segmental level. 
There was true homogeneity across both lungs in 3% of the 
cohort when defining heterogeneity as  ≥ 30% difference in 
tissue destruction.  Conclusion: Many LVR technologies for 
treatment of emphysema have focused on interlobar het-
erogeneity and target an entire lobe per procedure. Our ob-
servations suggest that a high proportion of patients with 
emphysema are affected by interlobar as well as intralobar 
heterogeneity. These findings prompt the need for a seg-
mental approach to LVR in the majority of patients to treat 
only the most diseased segments and preserve healthier 
ones.  © 2015 The Author(s)
Published by S. Karger AG, Basel 
 Key Words 
 Heterogeneity · Lung volume reduction · Chronic 
obstructive pulmonary disease · Bronchoscopy · Computed 
tomography 
 Abstract 
 Background: Although lobar patterns of emphysema het-
erogeneity are indicative of optimal target sites for lung vol-
ume reduction (LVR) strategies, the presence of segmental, 
or sublobar, heterogeneity is often underappreciated.  Ob-
jective: The aim of this study was to understand lobar and 
segmental patterns of emphysema heterogeneity, which 
may more precisely indicate optimal target sites for LVR pro-
cedures.  Methods: Patterns of emphysema heterogeneity 
were evaluated in a representative cohort of 150 severe 
(GOLD stage III/IV) chronic obstructive pulmonary disease 
(COPD) patients from the COPDGene study. High-resolution 
computerized tomography analysis software was used to 
measure tissue destruction throughout the lungs to com-
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 Introduction 
 Emphysema is pathologically defined as an ‘abnormal, 
permanent enlargement of air spaces distal to the termi-
nal bronchioles, accompanied by the destruction of al-
veolar walls’  [1] . The extent and distribution of these en-
largements vary within the lung, resulting in a heteroge-
neous spatial distribution of emphysema. The patterns 
and degree of emphysema heterogeneity within the lung 
can be defined and characterized to quantify the most dis-
eased portions of the lung with computed tomography 
(CT) density being used as an indicator for tissue destruc-
tion  [2] . Once quantified, the most diseased portions of 
the lung can potentially be selectively reduced as part of 
a lung volume reduction (LVR) procedure with the aim 
of improving patient quality of life. There is some evi-
dence that the degree of disease heterogeneity correlates 
with clinical efficacy after LVR  [3–5] . 
 There is currently no gold standard for defining het-
erogeneity. The National Emphysema Treatment Trial 
(NETT) quantified this by visually scoring CT scans. Each 
lung was divided into thirds to define three apical to bas-
al zones. Each zone was compared against the remaining 
two ipsilateral zones to evaluate heterogeneity  [5] . How-
ever, this method of visual scoring for emphysema sever-
ity is radiologist dependent and does not necessarily fol-
low anatomical lobar boundaries. Computerized quanti-
tative measurement tools have enabled more precise 
scoring of the lung. By doing so, the variability seen dur-
ing the radiologist-dependent visual scoring method is 
minimized, allowing for a user-independent result  [6] . 
 Advances in computerized quantitative measurement 
tools have also enabled a better understanding of how 
emphysema is spatially distributed at a sublobar level by 
assessing tissue destruction for individual bronchopul-
monary segments. Understanding which bronchopulmo-
nary segments are most diseased within a lobe may lead 
to a more precise understanding of which regions (e.g. 
segments and lobes) of the lung are the best targets for 
LVR procedures. 
 The current study aims to evaluate the patterns of em-
physema heterogeneity in GOLD stage III and IV patients 
using computerized quantitative measurement tools to ob-
jectively assess the pattern of emphysema by evaluating tis-
sue destruction throughout regions of the lung. The analy-
sis presented assesses heterogeneity between lobes as well 
as heterogeneity within lobes. We hypothesize that many 
patients have patterns of intralobar heterogeneity regard-
less of interlobar heterogeneity, and, therefore, many pa-
tients are not truly homogeneous at a segmental level. 
 Materials and Methods 
 Patient Selection and High-Resolution CT Analysis 
 A representative sample  [7–10] of 150 GOLD stage III/IV pa-
tients was selected from the COPDGene study, and their anony-
mized inspiratory high-resolution CT scans (HRCTs) were ac-
quired. Permission to use this dataset was obtained from the
COPDGene study committee, and institutional review board ap-
proval was obtained as part of the COPDGene study. Detailed in-
clusion criteria for the COPDGene study are discussed elsewhere 
 [11] . Briefly, the inclusion criteria were: age between 45 and 80 
years, minimum of a 10 pack-year smoking history, no previous 
surgical excision of at least one lung lobe (or LVR procedure), no 
active cancer under treatment, and no suspected lung cancer. The 
COPDGene study began enrolling patients in November 2007 and 
is expected to be completed by November 2017. The analysis of the 
subgroup presented in this paper was performed from May 2014 
to January 2015. The HRCTs were quantitatively analyzed using 
the commercially available Apollo version 2.1 software (VIDA Di-
agnostics, Coralville, Iowa, USA). For this study, the software pro-
vided a sublobar characterization of air volume and tissue mass 
volume for each of the segmental branches (RB1–10, LB1–10). See 
 figure 1 for a representation of sublobar segmentation from the 
VIDA Apollo software. An airway analysis was performed to ex-
tend airway paths to the sub-subsegmental generation, and man-
ual edits were made to fissure boundaries as needed. The editing 
mechanism is described in more detail in a previous publication 
 [12] . 
RB1
RB3
RB5
RB8 RB9
RB10
LB1
LB3
LB2
LB6
LB8LB4
LB9 LB10
LB5
 Fig. 1. Representation of sublobar segmentation from the VIDA 
Apollo software. Density and heterogeneity measurements are 
computed at the lobar and segmental levels. 
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 Defining Heterogeneity Indices 
 Relative low-density regions are indicative of high tissue de-
struction within the lung and/or the presence of hyperinflation 
 [13] . There are different methods that can be used to quantify these 
relatively low-density regions, including characterizing air volume 
and tissue mass for regions across the lung  [14] . In this study, air 
volume and tissue mass volumes were quantitatively assessed to 
compute an air volume to tissue mass ratio, a measure of hyperin-
flation and tissue destruction. The air volume to tissue mass ratio 
is the inverse of the previously published measure of lung density, 
the tissue to air ratio, and is directly correlated with disease sever-
ity  [5, 14] . During HRCT analysis, the right lung and left lung were 
each divided into three lobar regions, and each lobar region was 
divided into bronchopulmonary segments as follows: right upper 
lobe (RB1, RB2, RB3), right middle lobe (RB4, RB5), and right 
lower lobe (RB6, RB7, RB8, RB9, RB10); left upper lobe (LB1, LB2, 
LB3), lingula (LB4, LB5), and left lower lobe (LB6, LB8, LB9, LB10). 
 Tissue destruction was measured for each lobe and each bron-
chopulmonary segment. A ratio comparing the degree of tissue 
destruction for two regions of interest was compared to yield a 
heterogeneity index (equation 1). Depending on the type of re-
gions being compared, three different heterogeneity indices can be 
computed: lobar heterogeneity index, intralobar heterogeneity in-
dex, and segmental heterogeneity index as outlined by  figure 2 . A 
lobar heterogeneity index compares the degree of tissue destruc-
tion between two lobes. An intralobar heterogeneity index com-
pares the degree of tissue destruction between two bronchopulmo-
nary segments of the same lobar region. A segmental heterogeneity 
index compares the degree of tissue destruction between a bron-
chopulmonary segment and an ipsilateral lobe. In the latter two 
instances, the pattern of emphysema heterogeneity was dependent 
on individual segments. Individual segments are found to vary in 
size relative to the lobe and can therefore represent a small percent-
age of their respective lobe. For this reason, segments in the 10th 
percentile of lobe size were removed from the intralobar and seg-
mental heterogeneity index analyses to avoid concluding the exis-
tence of segmental heterogeneity based on a small portion of a 
given lobe. 
 
Heterogeneity index .
tissue destruction of
tissue destruction of
?
region of interest
region of comparison
 
(1)
 Heterogeneity Index Thresholds 
 A heterogeneity index was established to differentiate between 
low and high levels of heterogeneity. A heterogeneity index equal 
to 1.0 indicates that the two regions being compared are equiva-
lently diseased. Previous studies have denoted a difference of ap-
proximately 15% in tissue destruction to differentiate between low 
and high levels of heterogeneity  [6, 15] . A 15% difference is equiv-
alent to a heterogeneity index of 1.15, which is used as a threshold 
to differentiate heterogeneous disease from homogenous disease. 
Another, more stringent, heterogeneity index threshold of  ≥ 1.30 
was derived by doubling the commonly reported threshold of 15% 
and was used to verify a difference of at least 30% within a lobe. 
 Patterns of Emphysema Heterogeneity  
 Interlobar Heterogeneity 
 Interlobar heterogeneity indicates emphysema that is predom-
inant at a lobar level. The interlobar heterogeneity index can be 
used to describe patterns where a lobe on average is more diseased 
than its ipsilateral lobe. However, this does not take individual seg-
ments within a lobe into account. The segmental heterogeneity 
index can be used to evaluate the disease state of each segment as 
compared to the ipsilateral lobe. An example emphysema case is 
presented in  figure 3 . The right lung is perceived to be upper lobe 
predominant, but a segmental heterogeneity assessment reveals 
that not all segments of the right upper lobe are more diseased than 
its ipsilateral lower lobe. The left lung is also perceived to be upper 
lobe predominant. However, in this case, a segmental heterogene-
ity assessment reveals that all segments of the left upper lobe are 
more diseased than its ipsilateral lower lobe. The left upper lobe is 
truly more diseased than its ipsilateral lower lobe. Therefore, in-
Region of interest: lobe 
Region of comparison: ipsilateral
lobe* 
Region of interest: segment 
Region of comparison: most diseased
segment within respective lobe 
Region of interest: segment 
Region of comparison: ipsilateral
lobe* 
Lobar heterogeneity index Intralobar heterogeneity index Segmental heterogeneity index
*If the region of interest is associated with an upper lobe, the region of comparison is the lower lobe. If the
region of interest is associated with a lower lobe, the region of comparison is the upper lobe. If the region of
interest is associated with the right middle lobe or the lingula, the region of comparison is the more diseased
of the upper or lower lobe.   
 Fig. 2. Equations for three different heterogeneity indices. 
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terlobar heterogeneity can be grouped into two categories: per-
ceived interlobar heterogeneity and true interlobar heterogeneity. 
 Perceived Interlobar Heterogeneity. The average disease state of 
the lobe of interest is greater than that of the ipsilateral lobe. In this 
case, the lobe of interest must meet the lobar heterogeneity index 
threshold of 1.15. 
 True Interlobar Heterogeneity. The disease state of each seg-
ment in the lobe of interest is greater than in the ipsilateral lobe. In 
this group, which is a subset of perceived interlobar heterogeneity, 
all segments within the lobe of interest must meet the segmental 
heterogeneity index threshold of 1.15. 
 Intralobar Heterogeneity: Intralobar Heterogeneous 
Emphysema 
 The disease state of a segment in the lobe of interest is greater 
than that of another segment in the lobe of interest. In this case, at 
least one segment within the lobe of interest will meet the intralo-
bar heterogeneity index. Two analyses were performed to compute 
the level of heterogeneity. The initial analysis was performed using 
a heterogeneity index threshold of 1.15, and the second analysis 
was performed using a more stringent threshold of 1.30. Further-
more, each segment was assessed for how frequently it is the most 
diseased segment in its respective lobar region.
 Homogeneous Emphysema  
 A minor or no regional difference in the severity of emphysema 
is present between regions of the lung. This is defined with all three 
heterogeneity indices. In true homogenous emphysema, there is 
no heterogeneity in disease between or within lobes. Two analyses 
were performed to compute the frequency of homogeneity. The 
initial analysis was performed using a heterogeneity index thresh-
old of 1.15, and the second analysis was performed using a more 
stringent threshold of 1.30. 
 Statistical Analysis 
 Individual segments are found to vary in size relative to the lobe 
and can therefore represent a small percentage of their respective 
lobe. For this reason, segments in the 10th percentile of lobe size 
were removed from the intralobar and segmental heterogeneity 
index analyses to avoid concluding the existence of segmental het-
erogeneity based on a small portion of a given lobe. The patterns 
of heterogeneity were then assessed by calculating the percentage 
of the cohort that exhibited a heterogeneity index above a specified 
threshold for each lobe and lung using Microsoft Excel.
 Results 
 Demographic variables and lung function for all pa-
tients are reported in  table 1 . HRCTs of 75 patients with 
GOLD stage III emphysema and of 75 patients with 
GOLD stage IV emphysema were studied. All patients in 
the study cohort were current or former smokers, and a 
diagnosis of α1-antitrypsin deficiency was confirmed in 6 
patients. Quantifying the disease state at the segmental 
level in the right lower lobe of 2 patients was not possible 
due to atypical anatomy. The frequency of interlobar het-
erogeneity, intralobar heterogeneity, and homogeneity in 
the study cohort is summarized in  figure 4 and is detailed 
in the following sections. 
Right lung Left lung
RB1
LB1
LB2
LB3
LB4
LB5
LB6
LB8
LB9
RB2
RB6
RB8
RB9
RB3
RB4
RB5
Least
diseased
Most
diseased
 Fig. 3. Example patient with intralobar heterogeneous emphyse-
ma. The right upper lobe is perceived to be interlobar heteroge-
neous but is not considered to be truly interlobar heterogeneous 
because not all right upper lobe segments are more diseased than 
the lower lobe. The left upper lobe is truly interlobar heteroge-
neous because all left upper lobe segments are more diseased than 
the lower lobe. 
 Table 1. Patient dataset characterization
All patients
(n = 150)
GOLD stage III
(n = 75)
GOLD stage IV 
(n = 75)
Gender
Male 88 43 45
Female 62 32 30
Age, years 65 (8) 67 (8) 64 (8)
FVC% pred. 66 (16) 75 (13) 57 (15)
FEV1% pred. 32 (11) 40 (5) 23 (5)
FEV1/FVC, % 48 (13) 56 (11) 40 (8)
Values are numbers or means (standard deviations). FVC% 
pred. = Forced vital capacity percent predicted; FEV1% pred. = 
forced expiratory volume in 1 s percent predicted.
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 Interlobar Heterogeneous Emphysema 
 The frequency of interlobar heterogeneity in the study 
cohort is presented in  table  2 . Sixty-five percent of the 
cohort was perceived to have interlobar heterogeneous 
patterns bilaterally. However, only 39% of the cohort had 
true interlobar heterogeneous patterns bilaterally. A clos-
er look at upper lobe predominant emphysema revealed 
that 42% of the cohort was perceived to be upper lobe 
predominant bilaterally, but only 26% of the cohort was 
truly upper lobe predominant bilaterally. 
 Intralobar Heterogeneous Emphysema 
 The frequency of intralobar heterogeneity in the study 
cohort is presented in  table 3 . In patients with intralobar 
heterogeneous emphysema, as defined by the intralobar 
heterogeneity index and a threshold of 1.15, it can be ob-
served that heterogeneity exists within the lung for near-
ly all patients. Using a more stringent threshold of 1.30, 
intralobar heterogeneity was found bilaterally in 63% of 
the cohort. 
 A closer look at intralobar heterogeneous emphysema 
to determine how frequently each segment was the most 
diseased in its respective lobe indicates that LB3 and RB3 
were the most diseased segments of the upper lobes, 56 
and 43% of the time, respectively. LB4 an RB4 were the 
most diseased segments of the lingula and right middle 
lobe, 79 and 67% of the time, respectively. LB6 and RB8 
were the most diseased segments of the lower lobe, 46 and 
51% of the time, respectively. 
 Homogeneous Emphysema 
 The frequency of true homogeneity in the study cohort 
is presented in  tables 4 ,  5 . These patients did not exhibit 
high levels of heterogeneity as determined by the lobar, 
segmental, and intralobar heterogeneity indices. As de-
fined by a threshold of 1.15, all patients in this cohort had 
a form of heterogeneity present within the right lung, and 
only 1% of the cohort was found to be truly homogeneous 
in the left lung. As defined by a more stringent threshold 
of 1.30, 16% of the cohort was truly homogeneous in the 
left lung, 8% of the cohort was truly homogeneous in the 
right lung, and only 3% of the cohort was truly homoge-
neous bilaterally. 
 Table 2. Frequency of interlobar heterogeneity in GOLD stage III/
IV patients
 Frequency of interlobar heterogeneity, %
per ceived as 
interlobar 
heterogeneitya
true interlobar 
heterogeneityb
Upper lobe
Left 53 40
Right 56 32
Both 42 26
Middle lobe/lingula
Left 47 35
Right 49 37
Both 31 19
Lower lobe
Left 16 4
Right 13 3
Both 7 1
At least one lobe of the lung
Left 78 57
Right 81 52
Both 65 39
HI = Heterogeneity index. a Lobar HI ≥1.15 for the lobe of 
interest. b Segmental HI ≥1.15 for all segments in the lobe of 
interest.
0
Either
upper
lobe
RUL LUL Both
upper
lobes
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lower
lobe
RLL LLL Both
lower
lobes
10
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Lobe of interest
Intralobar heterogeneity
Intralobar HI >1.15 for at least
one segment in lobe of interest
Perceived interlobar heterogeneity
Lobar HI >1.15 
True interlobar heterogeneity
Segmental HI >1.15 for all
segments in lobe of interest
True homogeneity
Lobar HI <1.15
Segmental HI <1.15
Intralobar HI <1.15
 Fig. 4. Frequency of disease heterogeneity and homogeneity in the 
study cohort for each upper and lower lobe. HI = Heterogeneity 
index; RUL = right upper lobe; LUL = left upper lobe; RLL = right 
lower lobe; LLL = left lower lobe. 
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 Discussion 
 The current study quantifies the pattern of heteroge-
neity based on HRCT analysis and the spatial distribution 
of tissue destruction throughout the lungs in GOLD stage 
III and IV patients. The results of the analysis presented 
indicate that approximately half of GOLD stage III and 
IV patients have true interlobar heterogeneity in either 
lung. True interlobar heterogeneity was exhibited in ei-
ther upper lobe in 46% of the cohort, and only 6% of the 
cohort exhibited true interlobar heterogeneity in either 
lower lobe. When considering intralobar heterogeneity, 
97% of the cohort exhibited heterogeneity in both lungs. 
True homogeneity in GOLD stage III and IV patients is 
uncommon.
 There are therapeutic reasons to characterize patterns 
of emphysema heterogeneity. LVR studies have found a 
correlation between the degree of heterogeneity and ef-
ficacy of treatment  [2, 6] . The NETT study in particular 
demonstrated that patients with an upper lobe predomi-
nant pattern of emphysema are most likely to benefit 
from LVR surgery  [15] . A study published by Higuchi et 
al.  [16] also found that homogeneous patterns of emphy-
sema may also indicate a risk for interlobar collateral ven-
tilation. Based on these associations, defining the pattern 
and degree of emphysema heterogeneity can assist in 
treatment planning and play a large role in personalized 
therapy by indicating which regions of the lung to reduce 
during an LVR procedure. 
 Traditionally, LVR procedures have been performed 
via surgery. However, with advances in technology, endo-
scopic techniques are quickly becoming the most feasible 
interventions for treatment of emphysema. Each endo-
scopic LVR technique differs in its mechanistic target 
and, therefore, safety and efficacy capability. According-
ly, each technique assesses different patient and disease 
characteristics, such as fissure integrity and collateral 
ventilation, to determine patient eligibility and LVR tech-
nique compatibility  [17–21] . Among these patient char-
acteristics, disease heterogeneity is also assessed but, typ-
ically, is not evaluated within a lobe. We hypothesize that 
assessing heterogeneity within a lobe may provide a more 
precise indication of where tissue destruction is most pro-
nounced in the lung and may therefore indicate which 
treatment approach and technique might theoretically 
benefit the patient most. Targeting only the most diseased 
segments during an LVR procedure allows less diseased 
segments of the lung to continue contributing to positive 
lung function after treatment, which may benefit patient 
efficacy. A randomized, controlled trial utilizing a seg-
mental approach is currently ongoing and may assist in 
identifying the impact of heterogeneity within a lobe and 
segmental treatment planning  [5] . 
 There are currently four endoscopic LVR techniques 
being investigated for patients with emphysema: valves, 
coils, sealants, and vapor  [17–21] . Due to intralobar col-
lateral ventilation, valve LVR technologies are limited to a 
lobar approach where an entire lobe is targeted during an 
LVR procedure. Coils can be placed segmentally but are 
recommended for and typically used to reduce an entire 
lobe. These lobar-approach LVR interventions may be ap-
propriate for patients with true interlobar heterogeneity, 
where the entire lobe is more diseased than its ipsilateral 
lobe. With a lobar treatment for truly interlobar heteroge-
neous disease, 46% of the patients could have unilateral 
upper lobe treatment, 26% of the patients could have bilat-
eral upper lobe treatment, and less than 10% of the patients 
could have a unilateral or bilateral lower lobe treatment. 
Vapor and sealant technologies are able to use a segmental 
approach, where individual bronchopulmonary segments 
can be targeted during an LVR procedure. With a segmen-
tal treatment for segmental heterogeneous disease, 44% of 
Table 3. Frequency of interlobar heterogeneity in GOLD stage III/
IV patients
Frequency of intralobar heterogeneity, %
emphysema is 
heterogeneous 
within a lobea 
emphysema is 
heterogeneous 
within a lobeb
Upper lobe
Left 57 29
Right 75 40
Both 44 17
Middle lobe/lingula
Left 44 31
Right 35 12
Both 13 3
Lower lobe
Left 91 59
Right 97 78
Both 89 49
At least one lobe of the lung
Left 97 73
Right 100 83
Both 97 63
HI = Heterogeneity index. a Intralobar HI ≥1.15 for at least one 
segment in the lobe of interest. b Intralobar HI ≥1.30 for at least 
one segment in the lobe of interest.
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 Table 4. Frequency of homogeneous emphysema in GOLD stage III/IV patients using a 15% heterogeneity 
threshold
Frequency of homogeneous emphysema, %
emphysema is not 
heterogeneous at 
lobar levela
emphysema is not
heterogeneous at 
segmental levelb
emphysema is not 
heterogeneous
within a lobec
emphysema is truly 
homogeneousd
Upper lobe Left 47 33 43 15
Right 44 29 25 9
Both 33 21 13 3
Middle lobe/lingula Left 53 33 56 23
Right 51 36 65 20
Both 35 19 34 6
Lower lobe Left 84 70 9 9
Right 87 68 3 2
Both 79 57 2 2
Entire lung Left 1
Right 0
Both 0
 HI = Heterogeneity index. a Lobar HI <1.15. b Segmental HI <1.15 for all segments in the lobe of interest.
c Intralobar HI <1.15 for all segments in the lobe of interest. d Lobar HI <1.15; segmental HI <1.15; intralobar
HI <1.15.
Table 5. Frequency of homogeneous emphysema in GOLD stage III/IV patients using a 30% heterogeneity 
threshold
Frequency of homogeneous emphysema, %
emphysema is not 
heterogeneous at 
lobar levela
emphysema is not 
heterogeneous at 
segmental levelb
emphysema is not 
heterogeneous
within a lobec
emphysema is truly 
homogeneousd
Upper lobe Left 65 54 71 42
Right 66 50 60 37
Both 57 40 47 25
Middle lobe/lingula Left 81 63 69 52
Right 81 69 88 61
Both 69 47 59 33
Lower lobe Left 93 81 41 39
Right 95 83 22 20
Both 89 74 13 11
Entire lung Left 16
Right 8
Both 3
HI = Heterogeneity index. a Lobar HI <1.30. b Segmental HI <1.30 for all segments in the lobe of interest. c Intralobar HI <1.30 
for all segments in the lobe of interest. d Lobar HI <1.30; segmental HI <1.30; intralobar HI <1.30.
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the patients could have bilateral upper lobe treatment, and 
over 85% of the patients could have a unilateral upper lobe 
treatment, unilateral lower lobe treatment, or bilateral low-
er lobe treatment. This strategy applies to a meaningfully 
higher portion of all patients because a segmental approach 
for LVR may be appropriate for patients with true inter- or 
intralobar heterogeneous emphysema. 
 Figure 5 shows tissue destruction at a segmental level 
as an example emphysema case. The right lung appears to 
be upper lobe predominant and the left lung appears to 
be homogeneous based on lobar level tissue destruction. 
A segmental heterogeneity assessment reveals that the pa-
tient has intralobar heterogeneous patterns of emphyse-
ma in both lungs. A lobar approach may target the right 
upper lobe, left upper lobe, or left lower lobe to reduce the 
most diseased segments of the lung. In doing so, the least 
diseased segments will also be reduced. An alternate, seg-
mental approach allows for a more personalized therapy 
of emphysema where segmental heterogeneity can be 
used to target only the most diseased segments and pre-
serve the less diseased segments. Furthermore, emphy-
sema severity is expected to worsen over time and re-
treatment may be needed as the disease progresses. Treat-
ing only the most diseased portions of the lung without 
reducing the less diseased portions of the lung will allow 
for a larger lung reserve for future LVR procedures.
 Specific patterns of emphysema heterogeneity have 
been attributed to different causes. Previous studies have 
shown that α1-antitrypsin deficiency is often associated 
with lower lobe predominant emphysema, and smoking-
induced chronic obstructive pulmonary disease (COPD) 
is often associated with upper lobe predominant emphy-
sema  [22] . The frequency of COPD has also been associ-
ated with occupational titles and exposure to certain air-
borne agents  [23] . It is possible that these factors could 
cause a bias in the pattern of emphysema heterogeneity 
in the current cohort. However, all patients of the cohort 
were current or former smokers, and 6 patients (4%) were 
confirmed to have a diagnosis of α1-antitrypsin deficien-
cy. COPD is often attributed to smoking, and about 1–3% 
of all emphysema patients are estimated to have α1-
antitrypsin deficiency  [24] . Because emphysema is a sub-
Right lung t lungfeL
Most diseased regions RB3 and RB9 3 and LB6BL
Least diseased regions RB1 and RB8 1 and LB9BL
Lobar LVR approach target Right upper lobe (includes RB1 least
diseased segment)
None: left lung is interlobar
homogeneous
Segmental LVR approach target 3 and LB6BL3BR
Right lung Left lung
Least
diseased
Most
diseased
RB1
LB1
LB2
LB3
LB4
LB5
LB6
LB8
LB9
RB2
RB3
RB6
RB4
RB5RB8
RB9
 Fig. 5. Example patient with intralobar heterogeneous emphysema. The left lung is interlobar homogenous but 
exhibits intralobar heterogeneity. The right upper lobe is perceived to be interlobar heterogeneous but is not 
considered to be truly interlobar heterogeneous because not all segments are more diseased than the lower lobe. 
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set of COPD, an increase in this percentage is expected 
for COPD patients with α1-antitrypsin deficiency. The 
study cohort represented a similar population, and we 
therefore do not expect the results to drastically differ 
from representative GOLD stage III and IV patients. 
 Another limitation of the study is the use of low-den-
sity regions as a measure of tissue destruction due to em-
physema. While this likely has a strong correlation be-
cause the cohort is comprised of patients with a >10 pack-
year smoking history, there may be other causes of 
hyperinflation such as asthma and chronic bronchitis. 
However, because regions of hyperinflation are targeted 
for LVR in these patients, it was chosen as the best mea-
surement for heterogeneity analysis in this paper  [25] . 
Other measures of emphysema could be used with the 
same heterogeneity equations.
 Conclusion 
 On detailed CT analysis, the spatial distribution of em-
physema is heterogeneous through the whole lung in the 
majority of severe emphysematous patients. Further 
studies are needed to understand why some patients de-
velop disease in a particular pattern. Importantly, the pat-
tern of emphysema heterogeneity could be used to indi-
cate which LVR treatment approach and LVR technique 
will benefit the patient most. LVR techniques that are able 
to target individual segments provide a broader range of 
options in terms of determining how much and which 
portions of a lobe or lung to reduce per procedure. This 
may prove beneficial especially in patients with intralobar 
heterogeneity. LVR techniques that are limited to target-
ing an entire lobe per procedure may unintentionally tar-
get and reduce less diseased portions of the lobe during 
treatment. 
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